Becton Dickinson EBIT 2010-2024 | BDX

Becton Dickinson annual and quarterly EBIT history from 2010 to 2024. EBIT can be defined as earnings before interest and taxes.
  • Becton Dickinson EBIT for the quarter ending June 30, 2024 was $0.602B, a 10.05% increase year-over-year.
  • Becton Dickinson EBIT for the twelve months ending June 30, 2024 was $2.125B, a 5.51% decline year-over-year.
  • Becton Dickinson 2023 annual EBIT was $2.111B, a 7.53% decline from 2022.
  • Becton Dickinson 2022 annual EBIT was $2.283B, a 1.42% increase from 2021.
  • Becton Dickinson 2021 annual EBIT was $2.251B, a 146.82% increase from 2020.
Becton Dickinson Annual EBIT
(Millions of US $)
2023 $2,111
2022 $2,283
2021 $2,251
2020 $912
2019 $1,760
2018 $1,509
2017 $1,522
2016 $1,430
2015 $1,074
2014 $1,606
2013 $1,255
2012 $1,558
2011 $1,665
2010 $1,582
2009 $1,590
Becton Dickinson Quarterly EBIT
(Millions of US $)
2024-06-30 $602
2024-03-31 $734
2023-12-31 $438
2023-09-30 $351
2023-06-30 $547
2023-03-31 $627
2022-12-31 $586
2022-09-30 $489
2022-06-30 $537
2022-03-31 $566
2021-12-31 $691
2021-09-30 $84
2021-06-30 $492
2021-03-31 $433
2020-12-31 $1,242
2020-09-30 $-317
2020-06-30 $359
2020-03-31 $369
2019-12-31 $501
2019-09-30 $112
2019-06-30 $626
2019-03-31 $136
2018-12-31 $886
2018-09-30 $576
2018-06-30 $511
2018-03-31 $187
2017-12-31 $235
2017-09-30 $491
2017-06-30 $-224
2017-03-31 $445
2016-12-31 $810
2016-09-30 $97
2016-06-30 $516
2016-03-31 $465
2015-12-31 $352
2015-09-30 $295
2015-06-30 $137
2015-03-31 $293
2014-12-31 $349
2014-09-30 $401
2014-06-30 $446
2014-03-31 $381
2013-12-31 $378
2013-09-30 $77
2013-06-30 $405
2013-03-31 $381
2012-12-31 $392
2012-09-30 $389
2012-06-30 $449
2012-03-31 $383
2011-12-31 $337
2011-09-30 $364
2011-06-30 $447
2011-03-31 $440
2010-12-31 $413
2010-09-30 $316
2010-06-30 $423
2010-03-31 $414
2009-12-31 $430
2009-09-30 $379
2009-06-30 $432
2009-03-31 $361
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $67.812B $20.178B
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $78.143B 21.32
Cardinal Health (CAH) United States $29.438B 15.96
West Pharmaceutical Services (WST) United States $23.723B 48.46
Cooper (COO) United States $20.623B 29.35
Labcorp (LH) United States $20.401B 16.92
Align Technology (ALGN) United States $16.815B 32.18
Henry Schein (HSIC) United States $8.514B 16.22
Merit Medical Systems (MMSI) United States $6.067B 30.98
DENTSPLY SIRONA (XRAY) United States $3.508B 9.54
CONMED (CNMD) United States $2.312B 19.29
Patterson (PDCO) United States $1.855B 9.79
STAAR Surgical (STAA) United States $1.499B 55.31
Lifevantage (LFVN) United States $0.176B 23.40
Pro-Dex (PDEX) United States $0.154B 30.74